Considerable evidence supports the notion that brain angiotensin II (ANG II) plays an important role in the regulation of pressor responses, thirst, sodium appetite, and release of vasopressin [1] [2] [3] . The paraventricular nucleus of the hypothalamus (PVN) is known to be an important center for integrating the neural signals of pressor response 4,5 , the regulation of vasopressin release from the pituitary 6, 7 , and the mediation of the dipsogenic action of ANGII [5] . The medial septal area (MAS) as well as the PVN are brain structures involved in fluid electrolytic and cardiovascular regulation [8] [9] [10] [11] [12] [13] . Recently, 2 angiotensin receptor subtypes 1 and 2 have been identified on the basis of selective antagonists. Although most brain nuclei expressing ANG II receptors contain only 1 subtype, some nuclei express a mixture of AT 1 and AT 2 receptors 14, 15 . PVN is known to contain predominantly AT 1 subtype receptors 16, 17 , but it has been shown that the excitatory action of angiotensin on paraventricular neurons is also antagonized by the ANG II receptor subtype AT 2 18-20 . Both AT 1 and AT 2 sites are also found in the septum 21 . Because the septum has known anatomic connections with PVN 8,13,22 , we investigated the effect of previous PVN treatment with losartan, PD 123319, or [Sar 1 , Ala 8 ] ANG II (ANGII receptor antagonists) on the water and salt intake, urine and sodium excretion, and blood pressure responses induced by administration of ANG II into the (MSA).
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Methods
Male albino Holtzman rats weighing 250-300 grams were used in all experiments. The rats were individually housed in a temperature-controlled room (23±2°C) with a 12:12-hour light-dark cycle. Food pellets (Na + content -5 mEq/100 g) and water were available ad libitum except as noted. All experiments began at 09:00 AM. (PE-10 connected to a PE-50) inserted into the abdominal aorta through the femoral artery with the animals anesthetized with 2,2,2-tribromoethanol (20mg/100g body weight) on the day before the recording. The polyethylene tube was tunneled subcutaneously to the back of the rat and was connected to a Statham (P23Db) pressure transducer (Statham-Gould) coupled to a multichannel recorder (Physiograph, Narco Bio-Systems). The drugs were injected according to the same protocol described above.
Objective
Angiotensin II and [Sar 1 , Ala 8 ] ANG II (Sigma), losartan, and PD123319 (DuPont-Merck).
Sodium concentrations in urine samples were measured with a NOVA 1+1 apparatus.
At the end of the experiments, the rats were anesthetized with ether and a 10% saline and 10% formalin solution was perfused through the heart. The brains were removed, fixed in 10% formalin for 1 week, frozen, cut into 20-30 µm sections, and stained with hematoxylin.
Data are reported as means ± SEM. The results were statistically examined by using one-way analysis of variance (ANOVA), followed by comparisons between individual means by using the Newman-Keuls post hoc test. Differences at the 5% level (p<0.05) were considered significant.
Results
Only animals in which the injection was placed in the MSA were used in this study. The PVN parameters studied were observed in subjects that had the injection placed in the lateral parvocellular and medial posterior magnocellular subdivisions of the PVN but not in subjects in which the injections were placed in the fornix, zona incerta, reuniens thalamic nucleus, dorsal and medial parvocellular, or periventricular subdivisions of the PVN.
Effects of [Sar A stainless steel guide cannula (0.6 mm outer diameter, 0.33 mm inner diameter was implanted into MSA by using the following coordinates: 1.20 -1.00 mm anterior to the bregma in the midline, and to a depth of 4.2 mm from the dura mater. For cannula implantation into the PVN (unilaterally) the following coordinates were used: 0.2 -0.6 mm lateral to the sagittal line, 6.0 mm down the dura mater and 1.8 -2.0 mm posterior to the bregma. The cannula was secured to the top of the skull with dental cement and fastened with 2 screws. The insertion of a close fitting stylet kept the lumen free of debris and clots. A prophylactic dose of penicillin (30000 IU) was administered 3 days before and 3 days after surgery. After brain surgery, the animals were returned to individual metabolic cages, with free access to granular rations and tap water for 1 week until the day of the experiment. A dental needle (0.3 mm od) 2.0-mm longer than the cannula fixed to the skull was used for injections of all the drugs. The needle was connected by PE-tubing to a Hamilton-type syringe (5 µL) kept outside the cage. All drugs were injected in a 0.5-µL volumes for over 10-15 seconds.
To determine the accuracy of MSA or PVN placement, the animals were was offered drinking water immediately after ANG II (10 nmol) injection. Water ingestion (4 mL) within 15 minutes of the injection was presumptive evidence of correct positioning of the cannula into the MSA or PVN. This test was performed at least 72 hours prior to the experiment for water and sodium intake.
Seven days after brain surgery, water and 3% NaCl intake were measured in different groups after injection of saline (0.15 M NaCl) and ANG II (40 nmol) into the MSA. The effect of pretreatment with the ANG II receptor antagonists on ANG II-induced water or 3% NaCl intake was tested with [Sar Five days after brain surgery, catheters (PE-50 polyethylene tubing) were inserted with the animals anesthetized with 2,2,2-tribromoethanol (20 mg) per 100 grams of body weight into the superior vena cava via the right external jugular vein, with the opposite end externalized between the scapular. Two days after surgery, animals underwent the experimental session. After 12 hours of water and 3% NaCl solution deprivation, the catheters were connected to 10-mL syringes driven by a Harvard Apparatus infusion pump. Intravenous infusion of hypotonic saline (0.08 M at 1.5 mL/ h) was started to promote urinary flow, and 3 hours were allowed for equilibration. Urine excretion was recorded at 30-minute intervals for 2 hours after injection of the ANG II antagonists. Different groups received isotonic saline and ANG II into the MSA, and the ANG II antagonists into the PVN 15 minutes before ANG II.
Mean arterial pressure (MAP) was recorded in unanesthetized and unrestrained rats through polyethylene tubing 123319 into the PVN produced no alterations in water and salt intake.
Effects The urinary response of rats treated with ANG II and of rats pretreated with the antagonists is summarized in figure 3 . Analysis of variance applied to the 2-hour cumulative urine excretion indicated a significant difference between groups, F(4,44) = 14.13 (p<0.05). Cumulative urine excretion induced by ANG II was inhibited in animals previously treated with [Sar 1 , Ala 8 ] ANG II and PD 123319, but with no significant differences when compared with the saline controls, whereas previous injection of losartan decreased the urine excretion induced by ANG II indicating a significant difference when compared with saline controls.
Analysis of variance for the 2-hour cumulative sodium excretion data showed a significant difference between groups, F(4,44) = 24.73 (p<0.05). As can be seen in figure 4 Water intake (ml/120min) The injection of ANG II (10 nmol/0.5 µL) into the MSA, of conscious normotensive rats (MAP = 114±4 to 123±6 mmHg in different groups) produced an immediate large increase in MAP (∆MAP = 24±4 mmHg) compared to the results when only (0.15 M NaCl) was injected into the MSA (6±2 mmHg) (fig. 5) . The largest pressor response after ANG II injection into the MSA was reached within 3 minutes, with 10-30 minutes needed for the values to return to baseline.
Previous injection of [Sar 1 , Ala 8 ] ANG II (40 nmol) and losartan (10 nmol) into the PVN fully eliminated whereas PD 123319 (40 nmol) partially blocked the pressor response induced by ANG II injection.
Discussion
The results of the present study confirm reports that the dipsogenic and sodium intake action of centrally administered ANG II can be stopped by AT 1 receptor antagonist 24, 25 . In addition, the data show that the AT 2 receptor antagonist, PD 123319, also causes a marked reduction in the effects of ANG II on water and sodium intake. After injection of losartan into the PVN, the effects of MSA injection of ANG II on water and sodium ingestion were stopped, indicating that the actions of ANG II were exerted through AT 1 receptors. However, PD 123319 injected into the PVN also inhibited the effects of ANG II, although these effects were not as strong as those observed for losartan.
The present data also show that the AT 1 receptor antagonist causes a reduction in the effects of ANG II on water and sodium excretion. After injection of PD 123319 into the PVN, the effects of injection of ANG II into the MSA on urine and sodium excretion were totally stopped, indicating that the actions of ANG II were exerted principally through AT 2 receptors.
The present data also show that the hypertensive effect of ANG II administered into the MSA was eliminated by losartan and reduced but not eliminated by PVN administration of PD 123319. Data about AT 2 antagonists centrally administered are controversial. Intracerebroventricular (icv) administration of the AT 2 antagonists, PD 123319, PD 123177, and CGP 42112 have shown inhibition, no change, or an increase in water and sodium intake and pressor response to icv ANG II 17 . Several works have shown inhibitory responses to icv administration of PD 123319 on water and salt intake, vasopressin release, and pressor responses to central ANG II in rats 7, [25] [26] [27] [28] , but central administration of PD 123177 or CGP 42112 has not been shown to interfere with these responses 24, 28 . PVN administration of CGP 42112A eliminated the diuretic, natriuretic, and kaliuretic effects of ANG II injected into the same area 29 . Functional evidence exists that ANG II exerts excitatory effects on neurons of the PVN and that these effects are antagonized by CGP 42112A 19 . The MSA actions of ANG II on water and sodium intake, urinary and sodium excretion, and increases in arterial blood pressure are dependent on coactivation of both AT 1 and AT 2 receptor subtypes. It has been demonstrated that PD 123319 and EXP-3174 (an active metabolite of losartan), administered icv eliminate the cardiovascular response to ANG II 28 . The cardiovascular and behavioral effects of PD 123319 were remarkably similar to those of substance P, suggesting that PD 123319 may act by releasing endogenous substance P. It has been suggested that the inhibitory effects of relatively high doses of PD 123319 injected icv may be due to action on central AT 1 receptors 30 . Both AT 1 and AT 2 receptor subtypes in the brain have effects similar to those of ANG II-induced water and NaCl intake 25 and eliminate the cardiovascular response to ANG II injected icv 29 or into the hypothalamus 31 . In summary, the AT 1 and AT 2 receptors of the MSA may influence the cardiovascular and hydroelectrolyte alterations induced by ANG II. The present data show that AT 1 receptors of the PVN eliminate the water and sodium intake and the blood pressure response, and attenuate the diuretic and natriuretic actions of ANG II injected into the MSA. The AT 2 receptors of PVN play a role in blocking urine and sodium excretion, and alter the water and sodium intake and the pressor response induced by injection of ANG II into the MSA. These data suggest that MSA efferents may release ANG II, which acts as a neurotransmitter within PVN, resulting in postsynaptic effects that in turn influence fluid-electrolyte and blood pressure control as has been demonstrated by connections with the subfornical organ and supraoptic nucleus and septal area 32 . 
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